Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Derek A Wainwright

Showing results (51-60 of 90) with videos related to

Pageof 9
Sort By:
Pigment Cell & Melanoma Research|January 30, 2016
Functional cloning of a gp100-reactive T-cell receptor from vitiligo patient skinJared Klarquist, Jonathan M Eby, Steven W Henning, et al.
Oncotarget|December 17, 2017
Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence <i>in situ</i> hybridization (FISH) to select the optimal patients for matched therapy?Young Kwang Chae, Ayush Arya, Lauren Chiec, et al.
Current Opinion in Behavioral Sciences|May 4, 2019
The interplay among psychological distress, the immune system, and brain tumor patient outcomesSebastian Otto-Meyer, Jan Lumibao, Eugene Kim, et al.
Pigment Cell & Melanoma Research|February 24, 2010
Reduced skin homing by functional Treg in vitiligoJared Klarquist, Cecele J Denman, Claudia Hernandez, et al.
Brain, Behavior, and Immunity|February 10, 2017
Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastomaLijie Zhai, Erik Ladomersky, Carlos R Dostal, et al.
Brain, Behavior, & Immunity - Health|March 20, 2020
A retrospective survival analysis of Glioblastoma patients treated with selective serotonin reuptake inhibitorsSebastian Otto-Meyer, Rian DeFaccio, Corey Dussold, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 31, 2015
Dendritic Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant GliomaMahua Dey, Alan L Chang, Jason Miska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2014
Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumorsDerek A Wainwright, Alan L Chang, Mahua Dey, et al.
Oncoimmunology|February 7, 2019
Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg <i>et al</i>. (2017)Lijie Zhai, Erik Ladomersky, Kristen L Lauing, et al.
Oncoimmunology|September 14, 2016
Improving vaccine efficacy against malignant gliomaErik Ladomersky, Matthew Genet, Lijie Zhai, et al.
Pageof 9

Showing results (51-60 of 90) with videos related to

Sort By:
Pageof 9
Pigment Cell & Melanoma Research|January 30, 2016
Functional cloning of a gp100-reactive T-cell receptor from vitiligo patient skinJared Klarquist, Jonathan M Eby, Steven W Henning, et al.
Oncotarget|December 17, 2017
Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence <i>in situ</i> hybridization (FISH) to select the optimal patients for matched therapy?Young Kwang Chae, Ayush Arya, Lauren Chiec, et al.
Current Opinion in Behavioral Sciences|May 4, 2019
The interplay among psychological distress, the immune system, and brain tumor patient outcomesSebastian Otto-Meyer, Jan Lumibao, Eugene Kim, et al.
Pigment Cell & Melanoma Research|February 24, 2010
Reduced skin homing by functional Treg in vitiligoJared Klarquist, Cecele J Denman, Claudia Hernandez, et al.
Brain, Behavior, and Immunity|February 10, 2017
Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastomaLijie Zhai, Erik Ladomersky, Carlos R Dostal, et al.
Brain, Behavior, & Immunity - Health|March 20, 2020
A retrospective survival analysis of Glioblastoma patients treated with selective serotonin reuptake inhibitorsSebastian Otto-Meyer, Rian DeFaccio, Corey Dussold, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 31, 2015
Dendritic Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant GliomaMahua Dey, Alan L Chang, Jason Miska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2014
Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumorsDerek A Wainwright, Alan L Chang, Mahua Dey, et al.
Oncoimmunology|February 7, 2019
Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg <i>et al</i>. (2017)Lijie Zhai, Erik Ladomersky, Kristen L Lauing, et al.
Oncoimmunology|September 14, 2016
Improving vaccine efficacy against malignant gliomaErik Ladomersky, Matthew Genet, Lijie Zhai, et al.
Pageof 9